Tijdschrift voor kindergeneeskunde

, Volume 68, Issue 2, pp 183–188

Immunotherapie: effectiviteit en toepasbaarheid in de kindergeneeskunde

  • H. de Groot
Artikelen
  • 19 Downloads

Samenvatting

In dit artikel wordt een overzicht gegeven van de beschikbare literatuurgegevens aangaande de toepasbaarheid van immunotherapie in de kindergeneeskunde. Immunotherapie is zinvol bij kinderen met hooikoorts of mild tot matig astma met huisstofmijtallergie of katallergie en absoluut geïndiceerd bij levensbedreigende anafylaxie voor insectengif (wesp en bij). Er is geen plaats voor immunotherapie bij de behandeling van kinderen met astma met multipele allergieën: in dergelijke gevallen dient optimale behandeling plaats te vinden met sanering en farmacotherapie. Om veiligheidsredenen dienen de indicatie en uitvoering van immunotherapie te geschieden bij een specialist die ervaren is in de specifieke allergologische problematiek. Wat betreft de preventieve werking van immunotherapie zijn de schaarse voorlopige resultaten hoopgevend. Wellicht dient deze preventie in de toekomst uitgevoerd te worden op jongere leeftijd en met een ‘kindvriendelijker’ toedieningsvorm (nasaal of sublinguaal).

Summary

In this review an overview is presented of the literature concerning indications, contraindications, effectiveness and safety of immunotherapy in children. Immunotherapy is effective and indicated in children with pollinosis and mild to moderate asthma due to house dust mite or cat allergy. Life-threatening anaphylaxis due to insect venom allergy is an absolute indication for venom immunotherapy. Immunotherapy is less effective in children with multiple sensitizations, in this case optimal sanation and medical treatment are indicated. Immunotherapy should be initiated and evaluated by a specialist trained to treat atopic children. When immunotherapy is administered to children during the early phase of atopic disease it may modify the natural course, i.e. prevent new sensitizations and the development of asthma. In the future, other routes (nasal, sublingual), more acceptable for young children, will be indicated in selected patients.

Literatuur

  1. Holt PG, Sly PD. Allergic respiratory disease: strategic targets for primary prevention during childhood. Thorax 1997;52:1-4.CrossRefPubMedGoogle Scholar
  2. Hedlin G, Heilborn H, Lilja G, et al. Longterm follow-up of patients with a three year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:879-85.CrossRefPubMedGoogle Scholar
  3. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: Extended observations. J Allergy Clin Immunol 1998;101:298-305.CrossRefPubMedGoogle Scholar
  4. Dieges PH. Immunotherapie met extracten van inhalatie-allergenen. Geneesmiddelenbulletin 1993;27:8-11.Google Scholar
  5. Consensus: Indicaties voor immunotherapie met insectengif. Allergie Bulletin, 1997;10 (november):7-8.Google Scholar
  6. Consensus: Immunotherapie in de eerste lijn. Allergie Bulletin, 1997;10 (november):8-10.Google Scholar
  7. Malling HBJ. European Academy of Allergy and Clinical Immunology Position paper. Local immunotherapy. Allergy 1998;53:933-44.CrossRefPubMedGoogle Scholar
  8. Bousquet J, Lockey RF, Malling HBJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(suppl 44):1-42.Google Scholar
  9. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3.CrossRefGoogle Scholar
  10. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children B a 14-year study. Pediatrics 1968;5:793-802.Google Scholar
  11. Adkinson NF Jr, Egglestone P, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31.CrossRefPubMedGoogle Scholar
  12. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-74.PubMedGoogle Scholar
  13. Hauk P, Friedl K, Kaufmehl K, et al. Subsequent insect stings in children with hypersensitivity to Hymenoptera. J Pediatr 1995;126:185-90.CrossRefPubMedGoogle Scholar
  14. Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990;323:1601-3.PubMedCrossRefGoogle Scholar
  15. Hedlin G, Silber G, Naclerio R, et al. Comparison of the in vivo and in vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990;20:491-500.CrossRefPubMedGoogle Scholar
  16. Cantani A, Businco E, Benincori N, et al. A three year controlled study in children with pollinosis treated with immunotherapy. Ann Allergy 1984;53:79-84.PubMedGoogle Scholar
  17. Valovirta E. Capacity of specific immunotherapy in prevention of allergic asthma in children: The preventive allergy treatment study (pat). J Invest Allergol Clin Immunol 1997;7:369-70.Google Scholar
  18. Warner JO, Soothill JF, Price JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978:912-5.Google Scholar
  19. Gruber W, Eber E, Mileder P, et al. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients. Clin Exp Allergy 1999;29:176-81.CrossRefPubMedGoogle Scholar
  20. Hedlin G, Lindfors A, Browaldh L, et al. Immunotherapy in children with moderate asthma. J Allergy Clin Immunol 1994;93:250.Google Scholar
  21. Graft DF, Schuberth KC, Kagey-Sobotka A, et al. Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987;80:162-6.CrossRefPubMedGoogle Scholar
  22. Matloff SM, Bailit IW, Parks P, et al. Systemic reactions to immunotherapy. Allergy Proc 1993;14:347-50.CrossRefPubMedGoogle Scholar
  23. Bukantz SC, Lockey RF. Adverse effects and fatalities associated with allergen immunotherapy. In Bukantz SC, Lockey RF, editors. Allergen immunotherapy. New York: Marcel Dekker,1991:233-63.Google Scholar
  24. Businco L, Zannino L, Cantani A, et al. Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatr Allergy Immunol 1995;6:44-7.CrossRefPubMedGoogle Scholar
  25. Des Roches A, Paradis L, Menardo J-L, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-3.CrossRefPubMedGoogle Scholar
  26. Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extracts. J Allergy Clin Immunol 1997;99: 744-51.CrossRefPubMedGoogle Scholar
  27. Fahy J, Fleming H, Wong H, et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.PubMedGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2000

Authors and Affiliations

  • H. de Groot
    • 1
  1. 1.

Personalised recommendations